Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Novel tyrosine kinase inhibitors for renal cell carcinoma.

Dorff TB, Pal SK, Quinn DI.

Expert Rev Clin Pharmacol. 2014 Jan;7(1):67-73. doi: 10.1586/17512433.2014.862496. Epub 2013 Dec 2. Review.

PMID:
24308791
2.

Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.

Zivi A, Cerbone L, Recine F, Sternberg CN.

Expert Opin Drug Saf. 2012 Sep;11(5):851-9. doi: 10.1517/14740338.2012.712108. Epub 2012 Aug 4. Review.

PMID:
22861374
3.

Emerging targeted therapies in metastatic renal cell carcinoma.

Matrana MR, Atkinson B, Jonasch E, Tannir NM.

Curr Clin Pharmacol. 2011 Aug;6(3):189-98. Review.

PMID:
21827388
4.

Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.

Sonpavde G, Willey CD, Sudarshan S.

Expert Opin Investig Drugs. 2014 Mar;23(3):305-15. doi: 10.1517/13543784.2014.871259. Epub 2014 Jan 3. Review.

PMID:
24387233
5.

Pazopanib for the treatment of renal cancer.

Al-Marrawi MY, Rini B.

Expert Opin Pharmacother. 2011 May;12(7):1171-89. doi: 10.1517/14656566.2011.571206. Epub 2011 Apr 7. Review. Erratum in: Expert Opin Pharmacother. 2011 Jun;12(8):1349.

PMID:
21470066
6.

Emerging tyrosine kinase inhibitors for the treatment of renal cancer.

Iacovelli R, Albiges L, Escudier B.

Expert Opin Emerg Drugs. 2015 Sep;20(3):379-92. doi: 10.1517/14728214.2015.1047761. Epub 2015 May 19. Review.

PMID:
25982181
7.

Sorafenib for the management of advanced renal cell carcinoma.

Escudier B.

Expert Rev Anticancer Ther. 2011 Jun;11(6):825-36. doi: 10.1586/era.11.55. Review.

PMID:
21707277
8.

Differentiating mTOR inhibitors in renal cell carcinoma.

Pal SK, Quinn DI.

Cancer Treat Rev. 2013 Nov;39(7):709-19. doi: 10.1016/j.ctrv.2012.12.015. Epub 2013 Feb 21. Review.

9.

Molecularly targeted agents for renal cell carcinoma: the next generation.

Cowey CL, Hutson TE.

Clin Adv Hematol Oncol. 2010 May;8(5):357-60, 361-4.

PMID:
20551895
10.

New agents and new targets for renal cell carcinoma.

Philips GK, Atkins MB.

Am Soc Clin Oncol Educ Book. 2014:e222-7. doi: 10.14694/EdBook_AM.2014.34.e222. Review.

11.

Development of second-generation VEGFR tyrosine kinase inhibitors: current status.

Bhargava P, Robinson MO.

Curr Oncol Rep. 2011 Apr;13(2):103-11. doi: 10.1007/s11912-011-0154-3. Review.

12.

Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.

Coinu A, Petrelli F, Barni S.

Expert Rev Anticancer Ther. 2016;16(1):33-43. doi: 10.1586/14737140.2016.1109454. Epub 2015 Nov 4. Review.

PMID:
26535485
13.

Axitinib for the treatment of advanced renal cell carcinoma.

Akaza H, Fukuyama T.

Expert Opin Pharmacother. 2014 Feb;15(2):283-97. doi: 10.1517/14656566.2014.868436. Epub 2013 Dec 13. Review.

PMID:
24328549
14.

mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.

Barthélémy P, Hoch B, Chevreau C, Joly F, Laguerre B, Lokiec F, Duclos B.

Crit Rev Oncol Hematol. 2013 Oct;88(1):42-56. doi: 10.1016/j.critrevonc.2013.02.006. Epub 2013 Mar 20. Review.

PMID:
23523056
15.

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

Gupta S, Fishman M.

Expert Opin Pharmacother. 2011 Dec;12(18):2915-22. doi: 10.1517/14656566.2011.636032. Review. Erratum in: Expert Opin Pharmacother. 2012 Feb;13(2):291.

PMID:
22098229
16.

Cabozantinib use in renal cell carcinoma.

Neuwelt AJ, Mathur S, Johnson AT, Kessler ER, Bowles DW.

Drugs Today (Barc). 2017 May;53(5):299-307. doi: 10.1358/dot.2017.53.5.2623107. Review.

PMID:
28650002
17.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
18.

Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.

Mehta A, Sonpavde G, Escudier B.

Future Oncol. 2014 Aug;10(11):1819-26. doi: 10.2217/fon.14.120. Review.

PMID:
25325825
19.

Tivozanib: practical implications for renal cell carcinoma and other solid tumors.

Berge EM, Bowles DW, Flaig TW, Lam ET, Jimeno A.

Drugs Today (Barc). 2013 May;49(5):303-15. doi: 10.1358/dot.2013.49.5.1960218. Review.

PMID:
23724410
20.

Targeted therapies and the treatment of non-clear cell renal cell carcinoma.

Bellmunt J, Dutcher J.

Ann Oncol. 2013 Jul;24(7):1730-40. doi: 10.1093/annonc/mdt152. Epub 2013 Apr 26. Review.

PMID:
23625974

Supplemental Content

Support Center